Dogwood Therapeutics Accounts Payable

Dogwood Therapeutics (DWTX) currently reports a accounts payable of $410K as of June 2026. That compares with $500M in the prior-year period — down 99.9% year over year. Use the charts on this page to explore Dogwood Therapeutics's accounts payable history and peer comparisons.

Dogwood Therapeutics's accounts payable decreased from $500M to $410K — a 99.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dogwood Therapeutics reported $410K in accounts payable as of June 2026. That compares with $500M in the prior-year period — down 99.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $410K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Dogwood Therapeutics, and consider following DWTX for alerts when major investors trade the stock.

Dogwood Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $410K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DWTX with unrelated industries.